PDS Biotechnology Corporation (NASDAQ:PDSB) is in the list of top stocks to avoid today as the company shares are trading 9.52% or 0.24 points down from last closing price of $2.52, reaching $2.28 at last check. The PDSB share price has dropped in 2 of the last 5 days and is down -18.44% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 103,110 shares, and in total 118310 shares valued at $269747 were seen changing hands compared with 15200 shares valued at $38304 recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the PDSB stock.

PDS Biotechnology Corporation (PDSB) shares have notched a 3-month decline of about -18.44%, but has still tumbled -4.91% year to date. By comparison, the stock sank -75% over the past 12 months, while it slipped -0.4% over the 1 month. The company’s market cap is around $15.4M, with its short interest ratio standing at 1.86%.

In the current trading session for PDSB, the stock witnessed two major price actions, it rose to a high of $2.6 and was down as much as $2.1115 at one point. The high recorded is very low when compared to their 52-week high which is $2.02. The 52-week high is now at -81.23 distance from current price. Their recent low of $11.8 represents a 9.65% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for PDSB is $8.5, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

PDSB‘s last price was down -52.29% as compared to the average trading price of 50 days recorded at $4.78 while enlarging the period to 200 trading days, the average closing price was $2.63. At present, there are 6.11 million in the total number of common shares owned by the public and among those 3.17 million shares have been available to trade. The percentage of shares being held by the company management was 45.19% while institutions stake was 8.9%. The company has generated negative returns on equity over the last 12 months (-26.1%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the PDSB stock, there is another set of technicals that should be looked into and considered. Its -16.42% decline from moving average of $2.73 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 2.33 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of PDS Biotechnology Corporation — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $8.5 on shares of PDS Biotechnology Corporation (NASDAQ:PDSB), which corresponds to 286.36% upside potential than its current market price of $2.28 and implies potential despite the recent drop in the price. However, their current target price has fallen from $8.5 a month ago and is down handily from the consensus target of $8.5 a quarter ago.

In the last five years, the EPS of the company has been roughly -34.7%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.